Asthma Management Guidelines

Introduction to Asthma Management

The American Academy of Allergy, Asthma, and Immunology recommends a stepwise approach for asthma management, centered on inhaled corticosteroids (ICS) as the foundation of long-term control therapy, with treatment intensity adjusted based on disease severity and control status 1
Asthma management incorporates four essential components: assessment and monitoring, patient education, environmental control measures, and medication management, as suggested by the National Asthma Education and Prevention Program 1, 2

Assessment of asthma severity and control should be based on both impairment (current symptoms, functional limitations) and risk domains (future exacerbations, lung function decline), according to the Global Initiative for Asthma 3
Monitoring control involves regularly assessing symptom frequency and intensity, SABA use, peak expiratory flow (PEF) measurements, frequency of exacerbations, and pulmonary function testing with spirometry, as recommended by the American Thoracic Society 1, 2, 3

Inhaled corticosteroids are the most effective long-term control therapy and should be initiated as soon as possible in patients with persistent asthma, as stated by the National Heart, Lung, and Blood Institute 2
The stepwise approach involves stepping up therapy if asthma is not well controlled and stepping down therapy if asthma has been well controlled for at least 3 months, according to the Asthma Guidelines from the American College of Allergy, Asthma, and Immunology 1, 2
LABAs must never be used as monotherapy; patients must continue ICS even if symptoms improve significantly, as warned by the FDA and the American Academy of Allergy, Asthma, and Immunology 1

Allergen immunotherapy should be considered in patients with persistent allergic asthma when a clear relationship exists between symptoms and allergen exposure, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2
Comorbid conditions such as allergic rhinitis, sinusitis, GERD, OSA, obesity, and vocal cord dysfunction should be recognized and treated, as suggested by the American Thoracic Society and the American Academy of Sleep Medicine 2, 3

LABAs carry an FDA black box warning for increased risk of severe exacerbations, and should never be used as monotherapy for asthma, as warned by the FDA and the American Academy of Allergy, Asthma, and Immunology 1
Sedatives are absolutely contraindicated in asthmatic patients as they worsen respiratory depression, according to the American Thoracic Society and the National Institute for Health and Care Excellence 4

Underestimating severity, underuse of corticosteroids, poor inhaler technique, inadequate environmental control, failure to provide written action plans, and delaying specialist referral are common pitfalls to avoid in asthma management, as highlighted by the American Academy of Allergy, Asthma, and Immunology and the National Heart, Lung, and Blood Institute 1, 2, 7, 8

Regular assessment of control at every visit using validated tools, peak flow monitoring, height and weight monitoring in children on ICS, and influenza vaccination annually are essential for monitoring and follow-up, as recommended by the American Academy of Pediatrics and the Centers for Disease Control and Prevention 2, 8